

# Chronic Hepatitis B Virus Infection - Pipeline Insight, 2021

<https://marketpublishers.com/r/CC3D4F4AF35AEN.html>

Date: July 2021

Pages: 60

Price: US\$ 2,500.00 (Single User License)

ID: CC3D4F4AF35AEN

## Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "Chronic Hepatitis B Virus Infection - Pipeline Insight, 2021," report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Chronic Hepatitis B Virus Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Chronic Hepatitis B Virus Infection Understanding

#### Chronic Hepatitis B Virus Infection: Overview

Chronic hepatitis B virus infection is a global public health threat that causes considerable liver-related morbidity and mortality. It is acquired at birth or later via person-to-person transmission. Vaccination effectively prevents infection and chronic hepatitis B virus carriage. In chronically infected patients, an elevated serum hepatitis B virus DNA concentration is the main risk factor for disease progression, although there are other clinical and viral parameters that influence disease outcomes. In addition to liver biochemistry, virological markers, and abdominal ultrasonography, non-invasive assessment of liver fibrosis is emerging as an important assessment modality. Long-

term nucleos(t)ide-analogue therapy is safe and well tolerated, achieves potent viral suppression, and reduces the incidence of liver-related complications. However, a need to optimise management remains. Promising novel therapies are at the developmental stage.

'Chronic Hepatitis B Virus Infection - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Hepatitis B Virus Infection pipeline landscape is provided which includes the disease overview and Chronic Hepatitis B Virus Infection treatment guidelines. The assessment part of the report embraces, in depth Chronic Hepatitis B Virus Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Hepatitis B Virus Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Hepatitis B Virus Infection R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Hepatitis B Virus Infection.

## Chronic Hepatitis B Virus Infection Emerging Drugs Chapters

This segment of the Chronic Hepatitis B Virus Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Chronic Hepatitis B Virus Infection Emerging Drugs

**AB-729 (GalNAc-RNAi): Arbutus Biopharma**

AB-729 is a subcutaneously-delivered RNAi therapeutic targeted to hepatocytes that

inhibits viral replication and reduces all HBV antigens using our novel covalently conjugated GalNAc delivery technology. Currently, it is in Phase II stage of development to treat Chronic Hepatitis B virus infection.

#### VIR-2218: Vir Biotechnology

VIR-2218, an HBV-targeting siRNA, is designed to inhibit the production of all HBV proteins, including hepatitis B virus surface antigen (HBsAg), which in turn is hypothesized to remove the inhibition of T cell activity directed against HBV. We believe that achieving a functional cure for many HBV patients may be enabled by using VIR-2218 in combination with other agents. Currently, it is in Phase II stage of development to treat Chronic Hepatitis B virus infection.

Further product details are provided in the report.....

#### Chronic Hepatitis B Virus Infection: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Hepatitis B Virus Infection drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Chronic Hepatitis B Virus Infection

There are approx. 45+ key companies which are developing the therapies for Chronic Hepatitis B Virus Infection. The companies which have their Chronic Hepatitis B Virus Infection drug candidates in the most advanced stage, i.e. phase II include, Vir Biotechnology.

#### Phases

DelveInsight's report covers around 45+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Chronic Hepatitis B Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

## Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

### Chronic Hepatitis B Virus Infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Hepatitis B Virus Infection therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Hepatitis B Virus Infection drugs.

### Chronic Hepatitis B Virus Infection Report Insights

Chronic Hepatitis B Virus Infection Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

### Chronic Hepatitis B Virus Infection Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

## Unmet Needs

### Key Questions

#### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Chronic Hepatitis B Virus Infection drugs?

How many Chronic Hepatitis B Virus Infection drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Hepatitis B Virus Infection?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Hepatitis B Virus Infection therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Chronic Hepatitis B Virus Infection and their status?

What are the key designations that have been granted to the emerging drugs?

### Key Players

Arbutus Biopharma

Vir Biotechnology

Ascentage Pharma Group Inc.

Assembly Biosciences

Nucorion Pharmaceuticals, Inc.

Hoffmann-La Roche

Enyo Pharma

Qilu Pharmaceutical Co., Ltd.

Ascletis Pharmaceuticals Co., Ltd.

Xiamen Amoytop Biotech

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Romark Laboratories L.C.

Alios Biopharma Inc.

Antios Therapeutics, Inc

Jiangsu HengRui Medicine Co., Ltd.

Enanta Pharmaceuticals

Janssen Pharmaceuticals

Gilead Sciences

Replicor Inc.

Golden Biotechnology Corporation

Hepatera Ltd.

PharmaEssentia

Chong Kun Dang Pharmaceutical

Green Cross Corporation

Aligos Therapeutics

Sunshine Lake Pharma Co., Ltd.

Transgene

Tasly Tianjin Biopharmaceutical Co., Ltd.

GlaxoSmithKline

Henlix, Inc

Ionis Pharmaceuticals, Inc.

Altimune, Inc.

Shanghai HEP Pharmaceutical

Dong-A ST Co., Ltd.

Enyo Pharma

CHA Vaccine Institute Co., Ltd.

Dicerna Pharmaceuticals, Inc.

Vaccitech (UK) Limited

Fujian Cosunter Pharmaceutical Co. Ltd

Regeneron Pharmaceuticals

VenatoRx Pharmaceuticals

ISA Pharmaceuticals

Finch Therapeutics Group, Inc

Zhimeng Biopharma



VBI Vaccines Inc

Globelimmune

### Key Products

AB-729 (GalNAc-RNAi)

VIR-2218

APG-1387

ABI-H2158

NCO-48

RO7062931

EYP001a

QL-007

ASC22

Ypeginterferon alpha-2b

TQ-A3334

Nitazoxanide

JNJ-440

ATI-2173

HRS5091

EDP-514

JNJ-73763989

Selgantolimod

REP 2139-Mg

Antroquinonol

Myrcludex B

P1101

CKD-390

GC1102

ALG-000184

GLS4

TG1050

T101

ChAd155-hli-HBV

Serplulimab

IONIS-HBVRx

HepTcell

Hepalatile

DA-2802

EYP001a

CVI-HBV-002

DCR-HBVS

ChAdOx1-HBV

GST-HG141

Cemiplimab

VNRX-9945

ISA104

CP101

ZM-H1505R

VBI-2601

GS-4774

## Contents

Introduction

Executive Summary

Chronic Hepatitis B Virus Infection: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

Comparative Analysis

Ypeginterferon alpha-2b: Xiamen Amoytop Biotech

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

AB-729: Arbutus Biopharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

NCO-48: Nucorion Pharmaceuticals

Product Description

Research and Development

Product Development Activities  
Drug profiles in the detailed report.....  
Preclinical and Discovery Stage Products  
Comparative Analysis  
Drug name: Company name  
Product Description  
Research and Development  
Product Development Activities  
Drug profiles in the detailed report.....

Inactive Products  
Comparative Analysis  
Chronic Hepatitis B Virus Infection Key Companies  
Chronic Hepatitis B Virus Infection Key Products  
Chronic Hepatitis B Virus Infection- Unmet Needs  
Chronic Hepatitis B Virus Infection- Market Drivers and Barriers  
Chronic Hepatitis B Virus Infection- Future Perspectives and Conclusion  
Chronic Hepatitis B Virus Infection Analyst Views  
Chronic Hepatitis B Virus Infection Key Companies  
Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Chronic Hepatitis B Virus Infection

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Chronic Hepatitis B Virus Infection

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Chronic Hepatitis B Virus Infection - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/CC3D4F4AF35AEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CC3D4F4AF35AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970